| 1 |
Przespolewski A, Szeles A, Wang ES. Advances in immunotherapy for acute myeloid leukemia[J]. Future Oncol, 2018, 14(10):963-978.
|
| 2 |
Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study[J]. Leukemia, 2020, 34(5):1433-1443.
|
| 3 |
Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, et al. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000[J]. Cancer, 2018, 124(12):2534-2540.
|
| 4 |
Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL[J]. Blood, 2019, 134(26):2361-2368.
|
| 5 |
Sheffer M, Lowry E, Beelen N, et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells[J]. Nat Genet, 2021, 53(8):1196-1206.
|
| 6 |
Carlsten M, Jaras M. Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells[J]. Front Immunol, 2019, 10:2357.doi: 10.3389/fimmu.2019.02357. |
| 7 |
Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia[J]. Sci Transl Med, 2016, 8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341. |
| 8 |
Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation[J]. Blood, 2017, 130(16):1857-1868.
|
| 9 |
Kottaridis PD, North J, Tsirogianni M, et al. Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase I trial[J]. PLoS One, 2015, 10(6):e123416.doi: 10.1371/journal.pone.0123416. |
| 10 |
Ciurea SO, Soebbing D, Rondon G, et al. Interim results of a phase 2 clinical trial using Mb-IL21 ex vivo expanded nk cells to enhance graft versus leukemia effect for patients with myeloid malignancies after haploidentical transplantation[J]. Blood, 2017, 130(Supplement 1):3179.
|
| 11 |
Fehniger TA, Miller JS, Stuart RK, et al. A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia[J]. Biol Blood Marrow Transplant, 2018, 24(8):1581-1589.
|
| 12 |
Daher M, Rezvani K. Outlook for new car-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer[J]. Cancer Discov, 2021,11(1):45-58.
|
| 13 |
Arvindam US, van Hauten P, Schirm D, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells[J]. Leukemia, 2021, 35(6):1586-1596.
|
| 14 |
Morsink LM, Walter RB, Ossenkoppele G J. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia[J]. Blood Rev, 2019, 34:26-33.
|
| 15 |
Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors[J]. N Engl J Med, 2020, 382(6):545-553.
|
| 16 |
Introna M. CIK as therapeutic agents against tumors[J]. J Autoimmun, 2017, 85:32-44.
|
| 17 |
Peter Bader M, Huenecke S, Bönig H, et al. Preemptive treatment of minimal residual disease (MRD) with IL-15-activated cytokine-induced killer cells for the prevention of relapse in leukemia patients after allogeneic stem cell transplantation-results of a pilot study[J]. Biol Blood Marrow transplantation, 2016, 22(3):S43.
|
| 18 |
Maus MV. CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia[J]. Lancet, 2021, 398(10299):466-467.
|
| 19 |
Liu F, Cao Y, Pinz K, et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial[J]. Blood, 2018, 132(S1):901.
|
| 20 |
Daver N, Alotaibi AS, Bucklein V, et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments[J]. Leukemia, 2021, 35(7):1843-1863.
|
| 21 |
Sallman DA, Kerre T, Poire X, et al. Remissions in relapse/refractory acute myeloid leukemia patients following treatment with NKG2D CAR-T therapy without a prior preconditioning chemotherapy[J]. Blood, 2018, 132(Supplement 1):902.
|
| 22 |
Borot F, Wang H, Ma Y, et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies[J]. Proc Natl Acad Sci U S A, 2019, 116(24):11978-11987.
|
| 23 |
Lulla PD, Mamonkin M, Brenner M K. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia[J]. Cancer J, 2019, 25(3):199-207.
|
| 24 |
Tan Q, Zhang C, Yang W, et al. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2019, 7(1):232.doi: 10.1186/s40425-019-0709-7. |
| 25 |
Rotiroti MC, Buracchi C, Arcangeli S, et al. Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system[J]. Mol Ther, 2020, 28(9):1974-1986.
|
| 26 |
Magnani CF, Mezzanotte C, Cappuzzello C, et al. Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with sleeping beauty transposon for the treatment of acute lymphoblastic leukemia[J]. Hum Gene Ther, 2018, 29(5):602-613.
|
| 27 |
Xue L, Hu Y, Wang J, et al. T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia[J]. Cancer Manag Res, 2019, 11:6467-6476.
|
| 28 |
Krawczyk E, Zolov S N, Huang K, et al. T-cell Activity against AML improved by dual-targeted T cells stimulated through T-cell and IL7 receptors[J]. Cancer Immunol Res, 2019, 7(4):683-692.
|
| 29 |
Chapuis AG, Egan DN, Bar M, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant[J]. Nat Med, 2019, 25(7):1064-1072.
|
| 30 |
Zhao XY, Jiang Q, Jiang H, et al. Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo[J]. Eur J Immunol, 2020, 50(9):1374-1385.
|
| 31 |
Zuanelli BC, Lobaugh SM, Ruiz JD, et al. Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy[J]. Transplant Cell Ther, 2021, 27(9):771.e1-771.e10.
|